AstraZeneca Inks Deal With Scorpion Therapeutics to Target ‘Undruggable’ Cancers

AstraZeneca has signed a collaboration deal with Scorpion Therapeutics to discover, develop and commercialize precision medicines against previously hard-to-target cancer proteins, the so-called “undruggable” targets. Source: Drug Industry Daily

Continue ReadingAstraZeneca Inks Deal With Scorpion Therapeutics to Target ‘Undruggable’ Cancers

Sanofi Inks Deal With Korea’s ABL Bio to Develop Candidates for Neurodegenerative Diseases

Sanofi has agreed to buy exclusive global rights to develop Korean company ABL Bio’s preclinical antibody for the treatment of neurodegenerative conditions, including Parkinson’s disease. Purchase price: $75 million upfront,…

Continue ReadingSanofi Inks Deal With Korea’s ABL Bio to Develop Candidates for Neurodegenerative Diseases